The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Evolving response criteria for systemic mastocytosis in the KIT inhibitor era
Jason Gotlib, MD, Stanford University School of Medicine, Stanford, CA, discusses evolving response criteria for systemic mastocytosis in the era of KIT inhibitor therapies. Prof. Gotlib highlights findings from the EXPLORER (NCT02561988) and PATHFINDER (NCT03580655) trials of avapritinib, exploring the potential of pure pathologic response (PPR) criteria and molecular monitoring to improve treatment response assessment in advanced systemic mastocytosis. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This might provide a little bit of a runway for your discussions of indolent disease and that of Dan with advanced disease. These are my disclosures. I only bring this up because you’re very familiar with the minor and major criteria for mast cell disease, but I’m gonna focus on advanced disease. And amongst advanced disease, SM-AHN is the most common, accounting for 60 to 70% of cases, at least on our clinical trials...
This might provide a little bit of a runway for your discussions of indolent disease and that of Dan with advanced disease. These are my disclosures. I only bring this up because you’re very familiar with the minor and major criteria for mast cell disease, but I’m gonna focus on advanced disease. And amongst advanced disease, SM-AHN is the most common, accounting for 60 to 70% of cases, at least on our clinical trials. And I would consider, I’d call SM-AHN the rascal because it causes a lot of problems with interpreting responses.
Some issues about natural history for advanced disease: we’re very much focused on shorter life expectancy, reversion of organ damage, histopathologic responses, improving quality of life, and trying to make people live longer. Indolent disease is all about symptom mitigation, but with the new therapies, we may be able to offer more than that.
So this is really the KIT inhibitor therapy. You can almost tell that this is an AI-generated picture, but in 2017 we had midostaurin approved for advanced disease, in 2021 avapritinib was approved for advanced disease, in 2023 avapritinib was approved for indolent disease. And then we have bezuclastinib, who’s [unclear] for indolent disease based on the SUMMIT trial at the end of the year, and then sometime next year we hopefully expect the approval of it for advanced disease.
So these are some of the response criteria that have been used for mastocytosis. I’m going to focus on the evolution in particular from the International Working Group criteria to what we now hope to maybe evolve to, and that’s the pure pathologic response, or PPR.
So this is the global Phase II trial of midostaurin, and you can see there that we have waterfall plots showing reductions in tryptase level, bone marrow mast cell burden, splenomegaly. We see symptoms improved except for nausea and vomiting consistent with the drug. Skin rashes improve. The overall response rate was 60% and 45% was a major response, which was defined as a normalization of one or more organ damage findings. However, when this went to approval and the FDA and EMA did their post hoc analysis using the IWG criteria, you can see that the overall response rates per the IWG criteria were 17% per the FDA with only 2% CR rate, and 20% through the EMA. And the difference is that the EMA thought the clinical improvement, that is improvement of organ damage, was clinically relevant; the FDA did not. So you can see there’s a paucity of complete remissions using the IWG criteria.
So this is what we use or how we adjudicate responses. And like with Dan, we’ve been doing this for ten years with avapritinib and bezuclastinib. But the first thing is that we look at whether C-findings or mast cell-related organ damage is resolved. And these are different types of organ damage there in the second black box. If not resolved, we call it stable disease. If not resolved, but importantly there’s evolution of disease to AML, we call that progressive disease.
So if there is resolution of one of our organ damage findings, we call that clinical improvement. That’s what anchors all the responses. And if you’ve got, with that, a greater than 50% reduction in the mast cell aggregates in the bone marrow and the tryptase level by more than 50%, we call that a partial remission. And if the mast cell aggregates have disappeared or are eliminated and the tryptase level is less than 20, we call that a complete remission. And if the counts are completely resolved, we call that a complete remission with partial hematologic recovery.
Now there are challenges to these response criteria. The first is that again, organ damage anchors all responses, and we’ll talk about that. The second issue is that measurement of C-findings lacks precision: ascites and pleural effusion, hepatosplenomegaly, albeit we are doing more of this with MRIs to do volumetric determinations, bone lesions and changes in weight. Now the bone lesions and changes in weight, we’re not even using that on the avapritinib or bezuclastinib trials because they’re just too vague.
Also, lack of improvement or worsening of organ damage may not always reflect the SM component. It could be due to the AHN, it could be due to drug toxicity, it could be due to comorbid conditions or lingering toxicity from prior therapy. In this graphic, I show that the organ damage is really kind of dragging the responses down so that it’s more difficult, if you’re trying to achieve organ damage, to achieve a PR/CR. You can have complete disappearance of mast cell aggregates and tryptase level down to normal, but if you have an alkaline phosphatase that’s a little bit above normal, that’s considered stable disease if that’s your only C-finding. So it really can drag responses down.
So the feedback from the regulatory authorities when we were doing the initial trials using the criteria was that uncertainty exists about whether betterment of organ damage is related to the SM or AHN component or some combination of both. And they asked: are changes in the various laboratory findings that define CI sufficiently representative of clinical benefit, that is PFS or OS? And then are objective measures of mast cell disease such as mast cell burden and tryptase level considered by the regulatory health authorities to be—they think it’s a more compelling surrogate for long-term benefit, looking at the mast cell burden and the tryptase level.
So this is the difference between mIWG criteria and PPR criteria. The difference is that the PPR criteria only depend on the bone marrow mast cell aggregates and the tryptase level, and they have no linkage to whether there’s changes in organ damage. So you’re really talking about bone marrow mast cell aggregates, tryptase, and yes, we’re also looking at the KIT mutation and the CBC. We’re looking at the counts.
So when you look back at the avapritinib and bezuclastinib trials, and again these are not head-to-head trials, these are completely separate trials, you can see that for avapritinib, the overall response rate doesn’t really change when you go from mIWG to PPR, but the CR and CRh rate does go up from 30% to about 51%. And the same is true for bezuclastinib. You can see the overall response rate does go up, and the CR and CRh goes from 24% to 62% because organ damage is out of the equation.
Importantly, when we’ve done an analysis of mIWG and PPR in the avapritinib EXPLORER and PATHFINDER studies looking at 176 patients, we wanted to see whether achieving CR and PR versus not achieving that, and when you look at it through the IWG and the PPR, provide differences. And you can see that regarding the mIWG versus PPR, the curves look very much similar. And when you overlap them, and this is a landmark analysis, you have to have lived at least six months, you can see they completely overlap. So you’re not losing anything by doing PPR compared to IWG. So that’s a big win.
So what are the potential advantages? The advantages are that PPR avoids the challenges of really sorting through organ damage. And again, having served in these committees, that’s what we struggle with. Is organ damage related to the AHN, is it the SM or something else? This can routinely be used in clinical practice. It can be used with any patient that has a measurable mast cell burden, and it increases the pool of evaluable patients. There are patients who were evaluated for the trial and they didn’t have a C-finding, organ damage, and were not considered evaluable for the clinical trials. So that becomes a nonstarter or a nonissue really for PPR.
I also want to just touch on KIT mutations and this issue of assay sensitivity for the avapritinib trials. The limit of detection, or LOD, was down to 0.17% using droplet digital PCR. And you can see that the MRD negativity rate was 30% in the bone marrow in the Phase I study. In the Phase II PATHFINDER study, when the LOD went down to 0.02%, again with droplet digital PCR, the MRD negativity rate was 14%.
Now, this is one of the most important diagnostic issues in mast cell disease, and that is when you’re trying to find out whether a patient is KIT-positive or -negative, you need to use a very sensitive assay. And so in today’s world, using one that’s down to 0.01%, that has droplet digital PCR or allele-specific PCR, is very important. However, now there’s a [unclear assay name] sensitivity that was established through [unclear group name]. And this is generated by Rarity Bioscience and it’s down to 0.1%. So I think this is an assay that may be considered something we can use to assess MRD negativity in our patients. The other issue is whether, per the discussion yesterday looking at endpoints, this is a reasonable or useful surrogate that we could use to arrive at clinical benefit in our patients.
So I would just end with this proposal for a new response criteria system for advanced SM. This is a proposed collaboration between ECNM and AIM, where we actually use PPR as a tool for the first-level response in patients, and that is what we call Tier 1A, the so-called SM pathologic response. And this we would envision as a primary endpoint for trials. Tier 1B would be the AHN response. Although I have to say that it’s not always easy to adjudicate AHN in the context of these trials, there hasn’t been a very formal effort in doing so.
Tier 2 would be looking at the molecular response using a high-sensitivity assay. Tier 3 would be looking at clinical response, and that’s where we would invoke using the IWG criteria. And you can see it’s completely uncoupled from the pathologic or Tier 1A response. And then finally the Tier 4 response, which looks at symptoms and quality-of-life responses by using various PROs.
So I think that this is something that I hope would be looked upon by the FDA and EMA as something to adopt perhaps in lieu of the IWG criteria because they’re very easy and accessible. And I would just mention that these tiered response criteria are being evaluated or being designed in nonadvanced SM by Lindsay and Nate Boggs and others. So we’re trying to kind of build some complementary scheme for indolent disease.
So with that, I’m gonna end my talk. This—we were at the MPN workshop in the Carolinas just a month ago. I did get to go to Johns Island and take a photo of the Angel Oak tree, and that’s that. And I’ll overlay that with all our acknowledgments. Thank you.
AI-generated transcript. Please refer to the video as the authoritative source.
Read more...
